The recent identification of menstrual blood-derived stem cells (MenSCs) as a unique population of stem cells has created enormous promise for tissue engineering. In this study, after characterization of MenSCs in comparison with bone marrow-derived stem cells (BMSCs), the potential of MenSCs seeded into electrospun, biodegradable, nanofibrous scaffolds in order to engineer cartilage was evaluated.
Methods
MenSCs and BMSCs were isolated by discontinuous density gradient centrifugation and plastic adherence. After characterization of MenSCs compared with BMSCs, MenSC differentiation into chondrocytes was investigated on a nanofibrous scaffold with specific growth and differentiation factors. The scaffold was prepared from polycaprolactone (PCL) and its surface was modified by plasma treatment.
Results
Flow cytometric analysis of expanded cells showed that MenSCs typically express some surface and intracellular markers associated with BMSCs. But marked expression of OCT-4 and the absence of STRO1 distinguished them from mesenchymal stem cells obtained from bone marrow. Based on scanning electron microscope images, the MenSCs were strongly anchored to the highly porous scaffold, which they penetrated and proliferated on. The scaffold contained an extensive cartilage-like extracellular matrix with about 50% greater glycosaminoglycan content than control MenSCs differentiated in a two-dimensional (2D) culture system (p<0.05). Considerable amounts of proteoglycan were produced by the cells differentiated on the scaffold, as demonstrated by Alcian blue staining. Unlike undifferentiated MenSCs, cells differentiated on the scaffold had strong immunoreactivity with monoclonal antibody against collagen type II.
Conclusions
The evidence presented in this study introduces MenSCs as a suitable stem cell population candidate for cartilage tissue engineering.
PhinneyD.G.Isolation of mesenchymal stem cells from murine bone marrow by immunodepletion.Methods Mol Biol.2008; 449: 171–186. Medline. doi: 10.1007/978-1-60327-169-1_12
4.
LeeM.W., JangI.K., YooK.H., SungK.W., KooH.H.Stem and progenitor cells in human umbilical cord blood.Int J Hematol.2010; 92(1): 45–51. Medline. doi: 10.1007/s12185-010-0619-4
5.
Da SaccoS., SedrakyanS., BoldrinF.. Human amniotic fluid as a potential new source of organ specific pre-cursor cells for future regenerative medicine applications.J Urol.2010; 183(3): 1193–1200. Medline. doi: 10.1016/j.juro.2009.11.006
6.
MizunoH.Adipose-derived stem and stromal cells for cell-based therapy: current status of preclinical studies and clinical trials.Curr Opin Mol Ther.2010; 12(4): 442–449. Medline.
7.
RonzièreM.C., PerrierE., Mallein-GerinF., FreyriaA.M.Chondrogenic potential of bone marrow- and adipose tissue-derived adult human mesenchymal stem cells.Biomed Mater Eng.2010; 1; 20(3): 145–58.
8.
KazemnejadS., AllamehA., GharehbaghianA., SoleimaniM., AmirizadehN., JazayeriM.Efficient replacing of fetal bovine serum with human platelet releasate during propagation and differentiation of human bone marrow derived mesenchymal stem cells to functional hepatocytes-like cells.Vox Sang.2008; 95(2): 149–158. Medline. doi: 10.1111/j.1423-0410.2008.01075.x
9.
SchneiderR.K., NeussS., KnüchelR., Perez-BouzaA.Mesenchymal stem cells for bone tissue engineering.Pathologe.2010; 31(Suppl. 2): 138–146. Medline. doi: 10.1007/s00292-010-1329-7
10.
SinglaD.K.Stem cells in the infarcted heart.J Cardiovasc Transl Res.2010; 3(1): 73–78. Medline. doi: 10.1007/s12265-009-9151-4
ZhangM.J., LiuB., XiaW., SunZ.Y., LuK.H.Could cells from menstrual blood be a new source for cell-based therapies?Med Hypotheses.2009; 72(3): 252–254. Medline. doi: 10.1016/j.mehy.2008.10.021
17.
KazemnejadS., AllamehA., SoleimaniM.. Functional hepatocyte-like cells derived from human bone marrow mesenchymal stem cells on a novel 3-dimensional biocompatible nanofibrous scaffold.Int J Artif Organs.2008; 31(6): 500–507. Medline.
18.
ShabaniI., Haddadi-AslV., SeyedjafariE., BabaeijandaghiF., SoleimaniM.Improved infiltration of stem cells on electrospun nanofibers.Biochem Biophys Res Commun.2009; 382(1): 129–133.
19.
LiW.J., DanielsonK.G., AlexanderP.G., TuanR.S.Biological response of chondrocytes cultured in three-dimensional nano-fibrous poly (∊-caprolactone) scaffolds.J Biomed Mater Res.2003; 67: 1105–1114.
20.
LiW.J., TuliR., OkaforC.. A three-dimensional nanofibrous scaffold for cartilage tissue engineering using human mesenchymal stem cells.Biomaterials.2005; 26: 599–609. Medline. doi: 10.1016/j.biomaterials.2004.03.005
21.
MoutosF.T., GuilakF.Functional properties of cell-seeded three-dimensionally woven poly(epsilon-caprolactone) scaffolds for cartilage tissue engineering.Tissue Eng Part A.2010; 16(4): 1291–1301. Medline. doi: 10.1089/ten.tea.2009.0480
22.
LiW.J., CooperJ.A., MauckR., TuanR.S.Fabrication and characterization of six electrospun poly (α-hydroxy ester)-based fibrous scaffolds for tissue engineering applications.Acta Biomater.2006; 2(4): 377–385. Medline. doi: 10.1016/j.act-bio.2006.02.005
MosmannT.Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.J Immunol Methods.1983; 65(1-2): 55–63. Medline. doi: 10.1016/0022-1759(83)90303-4
26.
FarndaleR.W., ButtleD.J., BarrettA.J.Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue.Biochim Biophys Acta.1986; 883(2): 173–177.
VacantiJ.P., LangerR., UptonJ., MarlerJ.J.Transplantation of cells in matrices for tissue regeneration.Adv Drug Deliv Rev.1998; 33(1-2): 165–182. Medline. doi: 10.1016/S0169-409X(98)00025-8
29.
SmithL.A., MaP.X.Nano-fibrous scaffolds for tissue engineering.Colloids Surf B Biointerfaces.2004; 39(3): 125–131. Medline.
30.
YangJ., BeiJ., WangS.Improving cell affinity of poly (D, L-Lactide) film modified by anhydrous ammonia plasma treatment.Polym Adv Technol.2002(3–4);13: 220–226. doi: 10.1002/pat.177
31.
RyuG.H., YangW.S., RohW.. Plasma surface modification of poly (D, L-lactic-co-glycolic acid) film for tissue engineering.Surf Coat Tech.2005; 193(1-3): 60–64. doi: 10.1016/j.surfcoat.2004.07.062
32.
DuanY., WangZ., YanW., WangS., ZhangS., JiaJ.Preparation of collagen coated electrospun nanofibers by remote plasma treatment and their biological properties.J Biomater Sci Polym Ed.2007; 18(9): 1153–1164. doi: 10.1163/156856207781554019
PilgaardL., LundP., DurouxM.. Effect of oxygen concentration, culture format and donor variability on in vitro chondrogenesis of human adipose tissue derived stem cells.Regen Med.2009; 4(4): 539–548. Medline. doi: 10.2217/rme.09.28
35.
JanjaninS., LiW.J., MorganM.T., ShantiR.M., TuanR.S.Mold-Shaped, Nanofiber Scaffold-Based Cartilage Engineering Using Human Mesenchymal Stem Cells and Bioreactor.J Surg Res.2008; 149(1): 47–56. Medline. doi: 10.1016/j.jss.2007.12.788
JohnstoneB., HeringT.M., CaplanA.I., GoldbergV.M., YooJ.U.In vitro chondrogenesis of bone marrow-derived mesenchymal progenitor cells.Exp Cell Res.1998; 238(1): 265–272. Medline. doi: 10.1006/excr.1997.3858
38.
SakimuraK., MatsumotoT., MiyamotoC., OsakiM., ShindoH.Effects of insulin-like growth factor I on transforming growth factor beta1induced chondrogenesis of synovium-derived mesenchymal stem cells cultured in a polyglycolic acid scaffold.Cells Tissues Organs.2006; 183(2): 55–61. Medline. doi: 10.1159/000095509
39.
TewS.R., MurdochA.D., RauchenbergR.P., HardinghamT.E.Cellular methods in cartilage research: Primary human chondrocytes in culture and chondrogenesis in human bone marrow stem cells.Methods.2008; 45(1): 2–9. Medline. doi: 10.1016/j.ymeth.2008.01.006
40.
AignerT., StoveJ.Collagens—major component of the physiological cartilage matrix, major target of cartilage degeneration, major tool in cartilage repair.Adv Drug Deliv Rev.2003; 55(12): 1569–1593. Medline. doi: 10.1016/j.addr.2003.08.009
41.
ZhengL., FanH.S., SunJ.. Chondrogenic differentiation of mesenchymal stem cells induced by collagen-based hydrogel: An in vivo study.J Biomed Mater Res A.2010; 93(2): 783–792.
